Stay updated on LMB-100 and Pembrolizumab in Mesothelioma Clinical Trial
Sign up to get notified when there's something new on the LMB-100 and Pembrolizumab in Mesothelioma Clinical Trial page.

Latest updates to the LMB-100 and Pembrolizumab in Mesothelioma Clinical Trial page
- Check4 days agoNo Change Detected
- Check11 days agoChange DetectedThe expected modernization date for the ClinicalTrials.gov data ingest has been updated from June 2025 to July 2025.SummaryDifference0.5%
- Check18 days agoChange DetectedThe web page has been updated from version 2.16.2 to version 2.16.3.SummaryDifference0.0%
- Check26 days agoChange DetectedThe web page has been updated to reflect a modernization of the ClinicalTrials.gov data ingest scheduled for June 2025, along with an invitation for API users to provide input. Additionally, the revision number has been updated from v2.16.0 to v2.16.2.SummaryDifference0.8%
- Check40 days agoChange DetectedThe web page has been updated to version 2.16.0, replacing the previous version 2.15.2.SummaryDifference0.1%
- Check61 days agoChange DetectedThe web page has been updated from version 2.15.0 to version 2.15.2.SummaryDifference0.0%
- Check76 days agoChange DetectedThe webpage has undergone significant content changes, including the removal of detailed background information on mesothelioma treatments and the addition of a new study location and version revision. The focus has shifted to a specific study involving the drug LMB-100 and pembrolizumab.SummaryDifference56%
Stay in the know with updates to LMB-100 and Pembrolizumab in Mesothelioma Clinical Trial
Enter your email address, and we'll notify you when there's something new on the LMB-100 and Pembrolizumab in Mesothelioma Clinical Trial page.